SCHEMBL17601113

SCHEMBL17601113

Cc1nnnn1-c1ccnc(Cl)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDH1 O75874 2/20 0.43
▸ NOTUM Q6P988 1/20 0.39
▸ RPS6KA5 O75582 1/20 0.38
▸ LMNA P02545 4/20 0.35
▸ POLB P06746 1/20 0.34
▸ TRPV1 Q8NER1 3/20 0.32
▸ MAPT P10636 3/20 0.32
▸ HSP90AA1 P07900 2/20 0.32
▸ HPGD P15428 2/20 0.32
▸ HTT P42858 2/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ TP53 P04637 1/20 0.32
▸ NLRP1 Q9C000 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ CACNA1B Q00975 1/20 0.32
▸ APBA1 Q02410 1/20 0.32
▸ OGA O60502 1/20 0.32
▸ GRM5 P41594 1/20 0.32
▸ MAP3K14 Q99558 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17601389 0.75 IDH1 (0.47) IDH1RPS6KA5TRPV1MAPTTP53
SCHEMBL25234865 0.75 NOTUM (0.40) IDH1NOTUMRPS6KA5LMNAPOLB
SCHEMBL30166313 0.75 NOTUM (0.40) IDH1NOTUMRPS6KA5LMNAPOLB
SCHEMBL12435278 0.70 HTR3E (0.43) LMNAMAPTALDH1A1L3MBTL1P2RX7
SCHEMBL19100367 0.70 MAPT (0.51) LMNAPOLBMAPTHTTALDH1A1
SCHEMBL19100639 0.70 RPS6KA5 (0.38) RPS6KA5TRPV1HPGDALDH1A1OGA
SCHEMBL19211560 0.69 KDR (0.52) IDH1RPS6KA5ALDH1A1
SCHEMBL24054168 0.69 PDE10A (0.36) RPS6KA5TRPV1ALDH1A1GRM5P2RX7
SCHEMBL24053401 0.68 RPS6KA5 (0.36) RPS6KA5LMNAPOLBTRPV1MAPT
SCHEMBL473490 0.68 RAB9A (0.59) RPS6KA5LMNAPOLBMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12454529-B2 Piperazine cyclic ureas Sironax Ltd. (KY) 2025-10-28 — — US disclosed
CN-115697991-B Piperazine cyclic ureas 维泰瑞隆有限公司 2024-11-22 — — CN disclosed
US-20230203019-A1 Piperazine Cyclic Ureas SIRONAX (BEIJING) CO., LTD. (CN) 2023-06-29 — — US disclosed
US-20230203019-A1 Piperazine Cyclic Ureas SIRONAX (BEIJING) CO., LTD. (CN) 2023-06-29 — — US disclosed
US-20230203019-A1 Piperazine Cyclic Ureas SIRONAX (BEIJING) CO., LTD. (CN) 2023-06-29 — — US disclosed
CN-115697991-A Piperazine cyclic ureas 维泰瑞隆有限公司 2023-02-03 — — CN disclosed
US-10550099-B2 Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. (US) 2020-02-04 — — US disclosed
US-10550099-B2 Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. (US) 2020-02-04 — — US disclosed
EP-3194383-B1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS INC (US) 2019-11-06 — — EP disclosed
EP-3194383-B1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS INC (US) 2019-11-06 — — EP disclosed
US-20180134682-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2018-05-17 — — US disclosed
US-9815817-B2 Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. (US) 2017-11-14 — — US disclosed
US-9815817-B2 Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. (US) 2017-11-14 — — US disclosed
US-9815817-B2 Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. (US) 2017-11-14 — — US disclosed
EP-3194383-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS Forma Therapeutics, Inc. (US) 2017-07-26 — — EP disclosed
US-20160083365-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2016-03-24 — — US disclosed
WO-2016044781-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-03-24 — — WO disclosed
WO-2016044781-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-03-24 — — WO disclosed
US-20160083365-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2016-03-24 — — US disclosed
US-20160083365-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2016-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12454529-B2 Piperazine cyclic ureas RIPK1, RIPK3, RIPK4 IDH1 1984/4885NOTUM 4470/4885RPS6KA5 333/4885
US-10550099-B2 Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors IDH1, IDH3A, IDH3B IDH1 1/4885NOTUM 3588/4885RPS6KA5 1775/4885
US-20180134682-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH1, IDH3A, IDH3B IDH1 1/4885NOTUM 3588/4885RPS6KA5 1775/4885
US-20230203019-A1 Piperazine Cyclic Ureas RIPK1, RIPK3, RIPK4 IDH1 1984/4885NOTUM 4470/4885RPS6KA5 333/4885
US-20160083365-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH1, IDH3A, IDH3B IDH1 1/4885NOTUM 3588/4885RPS6KA5 1775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback